Cortisol and ACTH Response to Oral Dexamethasone in Obesity and Effects of Sex, Body Fat Distribution, and Dexamethasone Concentrations: A Dose-Response Study
Open accessThe DOI matches its OpenAlex record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
There is increasing evidence that the abdominal obesity phenotype may be associated with multiple alterations of the hypothalamic-pituitary-adrenocortical (HPA) axis activity in both sexes. Our hypothesis is that the lack of adequate cortisol suppression after the dexamethasone test may constitute an indirect marker of HPA axis hyperactivity in the presence of the abdominal obesity phenotype. A total of 34 normal-weight (13 men and 21 women) and 87 obese (36 men and 51 women), healthy, nondepressed subjects therefore underwent four different dexamethasone suppression tests randomly performed at varying intervals of at least 1 wk between each test. After a standard overnight 1-mg dexamethasone test, which served as a reference, three other tests were randomly performed at 1-wk intervals by administering 0.0035, 0.0070, and 0.015 mg oral dexamethasone per kilogram of body weight overnight. Blood samples were obtained for cortisol, ACTH, and dexamethasone. Results were analyzed separately in men and women as well as in normal-weight [body mass index (BMI) < or = 25 kg/m(2)] and overweight or obese (BMI > 25 kg/m(2)) subjects. The waist circumference and the waist to hip ratio (WHR) were used as markers of body fat distribution. After the standard 1-mg test, cortisol suppression was greater than 90% in all subjects. However, after each test, obese women had significantly higher values of percent cortisol and percent ACTH suppression than normal-weight women without any difference between obese and normal-weight men. Considering the response to the three variable-dose tests, a clear dose- response pattern (P < 0.001 for trend analysis) in percent cortisol and percent ACTH suppression was found in all subjects. After each test men had significantly higher dexamethasone levels than women, regardless of BMI. However, obese women, but not men, had significantly higher dexamethasone levels after each test than their normal-weight counterpart. Plasma dexamethasone concentrations were dose related (P < 0.001 for trend analysis) in all subjects, but the dose-related increase was significantly higher in normal-weight men than normal-weight women, whereas it was similar in obese subjects of both sexes. Stepwise multiple regression analysis revealed that both percent cortisol and percent ACTH variations were significantly and negatively influenced by dexamethasone levels, as well as by waist circumference values in men, and independently by BMI and waist circumference in women. However, in contrast to what has been found in men, a divergent contribution of BMI and waist circumference was found in women indicating that, with increasing waist values, a smaller suppression of the HPA axis was found with respect to that expected on the basis of BMI values. In conclusion, this study provides data of both physiological and physiopathological relevance. Overall, our data indicated that adjustment of the dexamethasone dose to body weight does not seem to substantially improve the sensitivity of the test, even in obese individuals, particularly when near-maximal doses are administered. However, this study demonstrated a highly significant effect of dexamethasone blood level concentrations on cortisol and ACTH suppression to low-dose dexamethasone tests. In addition, a significant effect of gender on postdexamethasone cortisol concentrations, suppression of the HPA axis, and dexamethasone levels were found, which may be dependent on related differences in both cortisol and dexamethasone metabolism. We showed that pituitary sensitivity to feedback inhibition by dexamethasone is preserved in obesity in both sexes even at low dosages. On the other hand, our data suggest that, at least in women, abdominal fat distribution may partially counteract the progressively greater suppressibility of the HPA axis that would be expected according to increasing BMI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
Glucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 1×
“Previous studies have shown that obesity and gender may have different effects on 11 -hydroxysteroid dehydrogenase activity and, consequently, on cortisol concentrations (37, 38) and HPA axis responsiveness to CRH and AVP (8).”
BackgroundCortisol secretion in relation to body fat distribution in obese premenopausal women
Mårin, P., Darin, N., Amemiya, T., Andersson, B., Jern, S., & Björntorp, P. (1992) · Metabolism · doi:10.1016/0026-0495(92)90171-6 · Cited by 458
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Pasquali, R., Cantobelli, S., Casimirri, F., Capelli, M., Bortoluzzi, L., Flamia, R., Labate, A. M., & Barbara, L. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.2.8393881 · Cited by 366
Self-citationMEIKLE, A. W. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb00733.x · Cited by 201 · cited 1×
“In fact, it is well known that, although dexamethasone availability is an important determinant of cortisol suppression (30–32), rates of dexamethasone metabolism vary widely among subjects (33).”
Background
Cited by
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0370 · Cited by 613
Incollingo Rodriguez, A. C., Epel, E. S., White, M. L., Standen, E. C., Seckl, J. R., & Tomiyama, A. J. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.08.014 · Cited by 422
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Lee, M.-J., Pramyothin, P., Karastergiou, K., & Fried, S. K. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.029 · Cited by 380
The Hypothalamic‐Pituitary‐Adrenal Axis Activity in Obesity and the Metabolic Syndrome
PASQUALI, R., VICENNATI, V., CACCIARI, M., & PAGOTTO, U. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.009 · Cited by 332
Self-citationGlucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239
“However, increased feedback sensitivity may not be applicable to obese men (Pasquali et al., 2002), although this sex is typified by a more-android adipose distribution!”
Stress, Hypothalamic-Pituitary-Adrenal Axis and Eating Disorders
Lo Sauro, C., Ravaldi, C., Cabras, P. L., Faravelli, C., & Ricca, V. (2008) · Neuropsychobiology · doi:10.1159/000138912 · Cited by 215
European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
Pasquali, R., Casanueva, F., Haluzik, M., van Hulsteijn, L., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0893 · Cited by 188
Self-citationGlucocorticoids and Type 2 Diabetes: From Physiology to Pathology
Di Dalmazi, G., Pagotto, U., Pasquali, R., & Vicennati, V. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/525093 · Cited by 168
“However, several studies have shown an increased responsiveness of the HPA axis to different stimuli in patients with abdominal obesity: these stimuli included food intake [85, 86], low-dose tetracosactide [87], and CRH-arginine vasopressin [88, 89], leading to the conclusion that abdominal adiposity is associated wit…”
BackgroundSelf-citationPosttraumatic stress disorder: A metabolic disorder in disguise?
Michopoulos, V., Vester, A., & Neigh, G. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.05.038 · Cited by 152
Waters, D. L., Qualls, C. R., Dorin, R. I., Veldhuis, J. D., & Baumgartner, R. N. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.5.536 · Cited by 112
Stress-induced cytokine responses and central adiposity in young women
Brydon, L., Wright, C. E., O'Donnell, K., Zachary, I., Wardle, J., & Steptoe, A. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803767 · Cited by 72
Approach to patients with pseudo-Cushing’s states
Scaroni, C., Albiger, N. M., Palmieri, S., Iacuaniello, D., Graziadio, C., Damiani, L., Zilio, M., Stigliano, A., Colao, A., Pivonello, R., et al. (2020) · Endocrine Connections · doi:10.1530/ec-19-0435 · Cited by 68
β-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome
Fransson, L., Franzén, S., Rosengren, V., Wolbert, P., Sjöholm, Å., & Ortsäter, H. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0189 · Cited by 59
Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese.
Ness‐Abramof, R., Nabriski, D., Apovian, C. M., Niven, M., Weiss, E., Shapiro, M. S., & Shenkman, L. (2002) · Obesity Research · doi:10.1038/oby.2002.166 · Cited by 58
Hryhorczuk, C., Décarie-Spain, L., Sharma, S., Daneault, C., Rosiers, C. D., Alquier, T., & Fulton, S. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.06.002 · Cited by 51
Veldhuis, J. D., Roelfsema, F., Iranmanesh, A., Carroll, B. J., Keenan, D. M., & Pincus, S. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1143 · Cited by 51
Holt, H. B., Wild, S. H., Postle, A. D., Zhang, J., Koster, G., Umpleby, M., Shojaee-Moradie, F., Dewbury, K., Wood, P. J., Phillips, D. I., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0629-9 · Cited by 48
“Subjects with decreased dexamethasone suppression have more rapid dexamethasone clearance [33], the rate of dexamethasone metabolism is increased in people in whom the suppression of cortisol during the dexamethasone suppression test is decreased [32, 33], and the rate of metabolic clearance of dexamethasone is higher…”
Aschbacher, K., Rodriguez-Fernandez, M., van Wietmarschen, H., Tomiyama, A. J., Jain, S., Epel, E., Doyle, F. J., & van der Greef, J. (2014) · Interface Focus · doi:10.1098/rsfs.2014.0020 · Cited by 48
Sharma, A. N., Aoun, P., Wigham, J. R., Weist, S. M., & Veldhuis, J. D. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00551.2013 · Cited by 39
Brief review: Glucocorticoid excretion in obesity
Müssig, K., Remer, T., & Maser-Gluth, C. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.01.008 · Cited by 36
Neidert, S., Schuetz, P., Mueller, B., & Christ-Crain, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0930 · Cited by 13
Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09934-7 · Cited by 4
“One participant from the second trial was excluded from the analysis as endogenous ACTH suppression was not sufficient (pre-dose ACTH concentration > 20 pg/mL compared to pre-dose ACTH concentration 5 pg/mL typically observed in DEX-suppressed individuals [ 28]).”
Metadata
- Authors
- Pasquali, R., Ambrosi, B., Armanini, D., Cavagnini, F., Uberti, E. C. D., Rio, G. D., Pergola, G. D., Maccario, M., Mantero, F., Marugo, M., Rotella, C. M., & Vettor, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2002-01-01
- Volume
- 87
- Issue
- 1
- Pages
- 166-175
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2163770481
- Cited by
- 141
- References
- 8
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.